Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Beroni Group's share price is €0.01.
Beroni Group's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.01. Hence, Beroni Group's PS Ratio for today is 1.11.
The historical rank and industry rank for Beroni Group's PS Ratio or its related term are showing as below:
FRA:6B9's PS Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.28 * Ranked among companies with meaningful PS Ratio only.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Beroni Group PS Ratio Related Terms
Beroni Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Beroni Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beroni Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beroni Group PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beroni Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Beroni Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Beroni Group's PS Ratio for today is calculated as
Beroni Group's Share Price of today is €0.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beroni Group's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Beroni Group (FRA:6B9) has a PS Ratio of 1.11 as of Jul. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beroni Group and its competitors.
Is Beroni Group's PS Ratio too high?
Beroni Group's current PS Ratio is 1.11. The Drug Manufacturers industry median PS Ratio is 2.28. Beroni Group's value of 1.11 is 51.3% below this industry median. Overall, Beroni Group has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Beroni Group's PS Ratio compare to PNXP and CRYM?
Beroni Group's PS Ratio of 1.11 can be compared against companies in the Drug Manufacturers industry. The industry median PS Ratio is 2.28. Beroni Group's value of 1.11 is 51.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.28, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beroni Group's current PS Ratio of 1.11 is 51.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Beroni Group and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beroni Group's current PS Ratio is 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beroni Group stock overvalued right now?
Beroni Group (FRA:6B9) has a current PS Ratio of 1.11. The current PS Ratio is 1.11 and 51.3% below the Drug Manufacturers industry median of 2.28. Beroni Group's overall GF Score™ is 57/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Beroni Group (FRA:6B9), the current PS Ratio is 1.11 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beroni Group Ltd is an Australia based company engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Geographically, the company operates in China.
57GF Score
Get the complete analysis for FRA:6B9
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6B9 has been successfully added to your 
